ANUHPHR.NS Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: March 06, 2026
Report Source: 2026 3rd Quarter Report
Anuh Pharma Ltd. Stock Analysis ANUHPHR.NS
Anuh Pharma Ltd. engages in the provision of manufacture of pharmaceuticals, medicinal chemical, and botanical products. The firm's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-TB, anti-malarial, antibacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate, erythromycin phosphate, and others. Its anti-malarial products include sulfadoxine, pyrimethamine, and others. The firm's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The firm's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone Na phosphate, mometasone furoate and clobetasol butyrate.
Read More Anuh Pharma Ltd (ANUHPHR.NS) Chart
Key Statistics of Anuh Pharma Ltd (ANUHPHR.NS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
₹81.00Volume
20.87KP/E Ratio (TTM)
16.7552 Week Range
Market Cap
7.99BAvg. Volume
51.83KDividend Yield
1.89%Financial Metrics & Statements of Anuh Pharma Ltd (ANUHPHR.NS)
FAQ's for Anuh Pharma Ltd (ANUHPHR.NS)
- According to Musaffa’s Shariah screening methodology, Anuh Pharma Ltd (ANUHPHR.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.